MicroRNAs in hepatocellular carcinoma treatment: Charting the path forward

doi:10.3748/wjg.v30.i11.1470

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 11

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3549)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

168

HTML

1879

Tables (1-1)

533

Sum=2580

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

287

Download

475

Sum=762

Mar 21, 2024 (publication date) through Mar 3, 2026

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Mar 21, 2024; 30(11): 1470-1474
Published online Mar 21, 2024. doi: 10.3748/wjg.v30.i11.1470

MicroRNAs in hepatocellular carcinoma treatment: Charting the path forward

Hong T Lin, Antonio F Alvarez Castaneda, Somashekar G Krishna, Khalid Mumtaz

Hong T Lin, Antonio F Alvarez Castaneda, Somashekar G Krishna, Khalid Mumtaz, Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States

Author contributions: Lin HT, Castaneda AFA, Krishna SG, and Mumtaz K have all contributed significantly to the writing of the manuscript; and all authors have read and approved the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Corresponding author: Khalid Mumtaz, MBBS, Associate Professor, Doctor, Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, The Ohio State University Wexner Medical Center, 395 W 12th Ave, Columbus, OH 43210, United States. khalid.mumtaz@osumc.edu

Received: November 21, 2023
Peer-review started: November 21, 2023
First decision: December 25, 2023
Revised: January 10, 2024
Accepted: February 28, 2024
Article in press: February 28, 2024
Published online: March 21, 2024
Processing time: 121 Days and 6.4 Hours

Core Tip

Core Tip: MicroRNAs (miRNAs) constitute a family of molecules with dual roles in both the development and prevention of cirrhosis and hepatocellular carcinoma (HCC). Depending on the type of miRNA and the target of interest, they have the potential to promote or inhibit angiogenesis, facilitate or inhibit immune invasion, and enable or halt cell cycle progression amongst other effects. When paired with safe and effective delivery vehicles, specific miRNAs show promise as targeted therapies for treating HCC. Nonetheless, owing to the intricate interactions within in vivo systems and limitations of current retrospective studies, further research is imperative to ensure the safety and efficacy of miRNA in HCC therapy.